Pura Vida Investments’s Ocular Therapeutix OCUL Stock Holding History

Pura Vida Investments’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-86,058	Closed	-$592K	–	99
2018 Q3	$592K	Buy	+86,058	New	+$540K	0.12%	98
2016 Q2	–	Sell	-6,000	Closed	-$58K	–	85
2016 Q1	$58K	Buy	+6,000	New	+$45.4K	0.03%	77

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Pura Vida Investments's OCUL Position: Q4 2018 in Review

Pura Vida Investments sold out of Ocular Therapeutix (OCUL) in Q4 2018, closing a stake of 86,058 shares — an estimated $592K sold.

Pura Vida Investments first reported a position in OCUL in Q1 2016 and held it in 2 quarters. The position peaked at $592K in Q3 2018. 69 funds tracked by Wall St. Rank hold OCUL as of Q4 2018.

Pura Vida Investments reported no remaining Ocular Therapeutix position as of Q4 2018 after selling out during the quarter.
Pura Vida Investments sold 86,058 Ocular Therapeutix shares in Q4 2018, an estimated $592K.
Pura Vida Investments first reported a position in Ocular Therapeutix in Q1 2016 and held it in 2 quarters.
Pura Vida Investments's Ocular Therapeutix position peaked at $592K in Q3 2018.
69 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2018.

Based on Pura Vida Investments's 13F filing for Q4 2018, filed 14 Feb 2019.